Healthy Clinical Trial
Official title:
WILD 5 Wellness: A 30-Day Intervention
Verified date | April 2018 |
Source | Beloit College |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to explore the efficacy and feasibility of an integrated, prescriptive, and trackable wellness intervention combining five wellness elements including exercise, mindfulness, sleep, social connectedness, and nutrition in Beloit College students. This program is called "WILD 5 Wellness: A 30-Day Intervention". Results for this study will be quantified through the use of standardized self-report questionnaires administered prior to and after students complete the WILD 5 program (Group 1) or 30 days of inactive participation (Group 2), and again approximately 30 days later when the initially inactive group (Group 2) will have just completed their active participation in the WILD 5 program and the first WILD 5 group (Group 1) will be approximately 30 days out from completion of their WILD 5 active portion. Data will be collected to evaluate participants' adherence and response to each element of WILD 5, a 5-pronged 30-day wellness intervention. It is expected that this 30-day integrated, prescriptive, and trackable program will be found to be an efficacious wellness intervention for Beloit College students as compared to the control (inactive) group of students not participating in the Active program.
Status | Completed |
Enrollment | 88 |
Est. completion date | December 5, 2017 |
Est. primary completion date | April 18, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Beloit College student enrolled in one or more of the following Spring 2017 academic courses: - Anthropology 201 01 "Research Designs: Sophomore Seminar in Anthropology" - Health and Society 240 B1 "Sophomore Seminar in Health and Society" - Spanish 218 "Health and Culture in the Spanish-Speaking World" - Biology 373 "Neuroscience Research" - Biology 215 "Emerging Diseases" Exclusion Criteria: - Individuals who are <18 years old - Individuals who are acutely suicidal and/or actively psychotic - Individuals who are pregnant or plan to get pregnant during the next 60 days, or who are not registered in one of the courses listed above. |
Country | Name | City | State |
---|---|---|---|
United States | Beloit College | Beloit | Wisconsin |
Lead Sponsor | Collaborator |
---|---|
Beloit College |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | WILD 5 Wellness Scale (W5WS), Assessing Change | Day 0, Day 30, Day 60, Day 30 + 6 months (Group 1), Day 60 + 6 months (Group 2) | ||
Primary | WILD 5 Wellness Elements (W5WE), Assessing Change | Day 0, Day 30, Day 60, Day 30 + 6 months (Group 1), Day 60 + 6 months (Group 2) | ||
Primary | WILD 5 Wellness Effort Scale (W5WES), Assessing Change | Day 0, Day 30, Day 60, Day 30 + 6 months (Group 1), Day 60 + 6 months (Group 2) | ||
Primary | WHO (World Health Organization) 5 Well-Being Index (1998 version), Assessing Change | Day 0, Day 30, Day 60, Day 30 + 6 months (Group 1), Day 60 + 6 months (Group 2) | ||
Primary | Social Connectedness Scale (SCS), Assessing Change | Day 0, Day 30, Day 60, Day 30 + 6 months (Group 1), Day 60 + 6 months (Group 2) | ||
Primary | Sleep Condition Indicator (SCI), Assessing Change | Day 0, Day 30, Day 60, Day 30 + 6 months (Group 1), Day 60 + 6 months (Group 2) | ||
Primary | Sheehan Disability Scale (SDS), Assessing Change | Day 0, Day 30, Day 60, Day 30 + 6 months (Group 1), Day 60 + 6 months (Group 2) | ||
Primary | Patient Health Questionnaire (PHQ-9), Assessing Change | Day 0, Day 30, Day 60, Day 30 + 6 months (Group 1), Day 60 + 6 months (Group 2) | ||
Primary | Mindful Attention Awareness Scale (MAAS), Day to Day Experiences, Assessing Change | Day 0, Day 30, Day 60, Day 30 + 6 months (Group 1), Day 60 + 6 months (Group 2) | ||
Primary | MIND ( Mediterranean-DASH Intervention for Neurodegenerative Delay)Diet, Assessing Change | Day 0, Day 30, Day 60, Day 30 + 6 months (Group 1), Day 60 + 6 months (Group 2) | ||
Primary | Generalized Anxiety Disorder (GAD-7), Assessing Change | Day 0, Day 30, Day 60, Day 30 + 6 months (Group 1), Day 60 + 6 months (Group 2) | ||
Primary | Eating and Appraisal Due to Emotions and Stress Questionnaire (EADES), Assessing Change | Day 0, Day 30, Day 60, Day 30 + 6 months (Group 1), Day 60 + 6 months (Group 2) | ||
Primary | Cognitive and Physical Functioning Questionnaire (CPFQ), Assessing Change | Day 0, Day 30, Day 60, Day 30 + 6 months (Group 1), Day 60 + 6 months (Group 2) | ||
Primary | Post Program Participant Questionnaire | The end of the 30 day active participation in WILD 5 Wellness for each group (1 and 2) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |